| Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients G Huls, DA Chitu, V Havelange, M Jongen-Lavrencic, ... Blood, The Journal of the American Society of Hematology 133 (13), 1457-1464, 2019 | 183 | 2019 |
| The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer RJ van Soest, AJM Nieuweboer, ES De Morree, D Chitu, AM Bergman, ... European Journal of Cancer 51 (17), 2562-2569, 2015 | 62 | 2015 |
| Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes EMP Cremers, TM Westers, C Alhan, C Cali, HA Visser-Wisselaar, ... haematologica 102 (2), 320, 2017 | 61 | 2017 |
| Clofarabine, high-dose cytarabine and liposomal daunorubicin in pediatric relapsed/refractory acute myeloid leukemia: a phase IB study NKA Van Eijkelenburg, M Rasche, E Ghazaly, MN Dworzak, T Klingebiel, ... haematologica 103 (9), 1484, 2018 | 39 | 2018 |
| Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS G Huls, DA Chitu, T Pabst, SK Klein, G Stussi, L Griskevicius, PJM Valk, ... Blood advances 4 (18), 4267-4277, 2020 | 25 | 2020 |
| Bortezomib maintenance therapy after induction with R-CHOP, ARA-C and autologous stem cell transplantation in newly diagnosed MCL patients, results of a multicenter phase II … JK Doorduijn, MC Minnema, MJ Kersten, PJ Lugtenburg, MR Schipperus, ... Blood 126 (23), 339, 2015 | 21 | 2015 |
| Genomic array as compared to karyotyping in myelodysplastic syndromes in a prospective clinical trial MJ Stevens‐Kroef, D Olde Weghuis, N ElIdrissi‐Zaynoun, ... Genes, Chromosomes and Cancer 56 (7), 524-534, 2017 | 18 | 2017 |
| Effects of budesonide on cabazitaxel pharmacokinetics and cabazitaxel-induced diarrhea: a randomized, open-label multicenter phase II study AJM Nieuweboer, AJM de Graan, P Hamberg, S Bins, RJ van Soest, ... Clinical Cancer Research 23 (7), 1679-1683, 2017 | 18 | 2017 |
| Bortezomib maintenance after R‐CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II … JK Doorduijn, JM Zijlstra, PJ Lugtenburg, MJ Kersten, LH Böhmer, ... British journal of haematology 190 (3), 385-393, 2020 | 15 | 2020 |
| Dutch Uro-Oncology Studygroup (DUOS). The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant … RJ van Soest, AJ Nieuweboer, ES de Morrée, D Chitu, AM Bergman, ... Eur J Cancer 51 (17), 2562-2569, 2015 | 15 | 2015 |
| Feasibility, SAR distribution, and clinical outcome upon reirradiation and deep hyperthermia using the hypercollar3D in head and neck cancer patients M Kroesen, N van Holthe, K Sumser, D Chitu, R Vernhout, G Verduijn, ... Cancers 13 (23), 6149, 2021 | 14 | 2021 |
| Distinct bone marrow immunophenotypic features define the splicing factor 3B subunit 1 (SF3B1)‐mutant myelodysplastic syndromes subtype C Duetz, TM Westers, FEM in’t Hout, EMP Cremers, C Alhan, ... British journal of haematology 193 (4), 798-803, 2021 | 11 | 2021 |
| Randomized maintenance therapy with azacitidine (Vidaza) in older patients (≥ 60 years of age) with acute myeloid leukemia (AML) and refractory anemia with excess of blasts … G Huls, D Chitu, V Havelange, M Jongen-Lavrencic, A van de Loosdrecht, ... Blood 130, 463, 2017 | 11 | 2017 |
| Rituximab‐PECC induction followed by 90Y‐ibritumomab tiuxetan consolidation in relapsed or refractory DLBCL patients who are ineligible for or have failed ASCT … PJ Lugtenburg, JM Zijlstra, JK Doorduijn, LH Böhmer, M Hoogendoorn, ... British Journal of Haematology 187 (3), 347-355, 2019 | 10 | 2019 |
| Assessing estimated velocity-depth models: Finding error bars in tomographic inversion DA Chiţu, MN Al-Ali, DJ Verschuur Geophysics 73 (5), VE223-VE233, 2008 | 9 | 2008 |
| A study on behalf of the HOVON89 study group.(2017). Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes EM Cremers, TM Westers, C Alhan, C Cali, HA Visser-Wisselaar, ... Haematologica 102 (2), 320-326, 0 | 9 | |
| TCF4 promotes erythroid development FEM In't Hout, J van Duren, D Monteferrario, E Brinkhuis, N Mariani, ... Experimental hematology 69, 17-21. e1, 2019 | 8 | 2019 |
| R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial MED Chamuleau, F Stenner, DA Chitu, U Novak, MC Minnema, P Geerts, ... The Lancet Haematology 10 (12), e966-e975, 2023 | 7 | 2023 |
| R‐CODOX‐M/R‐IVAC VERSUS DA‐EPOCH‐R IN PATIENTS WITH NEWLY DIAGNOSED HIGH‐RISK BURKITT LYMPHOMA: FINAL RESULTS OF A MULTI‐CENTER RANDOMIZED HOVON/SAKK TRIAL. M Chamuleau, F Stenner, D Chitu, U Novak, M Minnema, O Visser, ... Hematological Oncology 41, 2023 | 7 | 2023 |
| Dysplasia and PNH‐type cells in bone marrow aspirates of myelodysplastic syndromes TM Westers, C Alhan, HA Visser‐Wisselaar, DA Chitu, ... Cytometry Part B: Clinical Cytometry 104 (2), 162-172, 2023 | 7 | 2023 |
